Sasaki Laboratory


Atsuo Sasaki, PhD, at his office in the Vontz Center for Molecular Studies.

Atsuo Sasaki, PhD, an Assistant Professor in the Division of Hematology-Oncology, is creating a platform for rigorous study of the complex biochemistry that underlies the rapid growth of metastatic brain tumors. His work is a core component of the Brain Tumor Molecular Therapeutics Program, which seeks to understand the biological mechanisms of cancer’s spread to the brain and to translate that knowledge into more effective treatments. The effort is a partnership between the University of Cincinnati Gardner Neuroscience Institute and University of Cincinnati Cancer Institute.

In particular, Dr. Sasaki is zeroing in on the energy-guzzling nature of metastatic brain tumors, which differentiates them from normal brain cells as well as from metastases in other parts of the body.

“Normal cells in the brain don’t grow in number,” Dr. Sasaki explains. “Only tumor cells grow in the brain, expending vast amounts of energy while doing so. In addition, metastatic tumor cells tend to grow faster in the brain than anywhere else. For example, patients with lung cancer often experience their first symptoms as neurologic (rather than in the chest) because of the rapid development of brain metastasis from the primary site. Likewise, some metastasized brain tumors have the ability to divide more rapidly than other types of tumors, and the molecular mechanism for this phenomenon has been largely unknown.”

The secret to that rapid growth is energy utilization, Dr. Sasaki says, and this is the focus of his laboratory.

“Brain tumors grow very fast, and they need a significant amount of energy to accomplish this rapid cell division and proliferation,” he says. “You could liken them to large, gas-guzzling vehicles that use lots of fuel to get where they need to go. And, like gas-guzzling vehicles, these cancer cells in the brain require frequent trips to the gas station to fill up their tank.”

This, Dr. Sasaki says, is an inherent vulnerability and offers a potential opportunity to scientists. He explains that just as an automobile has an energy indicator – the fuel gauge – cancer cells also have an indicator of how much fuel they have remaining. If cells can be tricked into ignoring their fuel indicator, or if they can be tricked into thinking their fuel tank is full when in fact it is empty, they will die.

“If we can keep the tumor cells from going to the gas station for more fuel, they will expire,” Dr. Sasaki says. “We know that if this system is broken – if the cells run out of gas – they are going to die.”

Dr. Sasaki’s lab also will be studying the “soil and seed” aspect of metastatic brain tumors. Once a brain metastasis has taken root in the brain, it requires nutrition to grow. Cancer cells adapt so that they can utilize available nutrition. Preventing that adaptation, or preventing nutritional utilization, could be another path toward shutting down the ability of a brain metastasis to grow.

Once Dr. Sasaki develops a clear understanding of how cancer cells draw nutrition from the brain and how they know when to “return to the gas station for more energy,” he has the potential to translate his knowledge into treatments that can be tested in Phase I/II clinical trials by the UC Brain Tumor Center’s clinical team.

Dr. Sasaki brings a broad-based scientific background to UC. He was recruited from Harvard University, where he was an Instructor in Medicine. He earned his doctorate in molecular biology from the Kurume University School of Medicine in Kurume City, Japan, where he focused on cytokine signaling, the intercellular communication among protein molecules. His post-doctoral work, performed at the University of California, San Diego, focused on immune cell migration and tumor cell invasion.

“I have rigorous training that ranges from biochemistry to oncogene signaling,” Dr. Sasaki says. “I believe I have a unique viewpoint of cancer, and I hope to use that viewpoint to develop a robust brain tumor research program here at the UC Brain Tumor Center.”

While at Harvard, Dr. Sasaki was part of a research team that discovered a new mechanism by which a cell protein known as Ras can trigger persistent signaling, which can lead to cancer. An article about those findings was published online in three prestigious journals: Science Signaling (2011), Cancer Discovery (2011) and Nature Structural Molecular Biology (January 2013).

Kazutaka Sumita, MD, PhD, left, and and Atsuo Sasaki, PhD, at the Vontz Center for Molecular Studies.


  • Print This Page
  • Make an Appointment: Schedule Now
  • Sign up for our newsletter!
  • Hope Stories

    • Jim’s Story: Acromegaly / Pituitary Tumor

      Jim's Story: Acromegaly / Pituitary Tumor Four years later, Jim’s story just keeps getting better. Because four years after being treated for a pituitary tumor at the UC Brain Tumor Center, Jim continues to feel better and better. The size of his head has gone down....
    • Bob’s Story: Recurrent Glioblastoma

      Bob's Story: Recurrent Glioblastoma Glioblastomas come back. Sometimes sooner, sometimes later, but they always come back. “That’s the...
    • Lynne’s Story: Brain Metastasis

      Lynne's Story: Brain MetastasisSemiretired and working part-time at a restaurant, Lynne knew something was amiss when she looked at the cash register and then struggled to make her hands produce the correct amount of change. Could she have suffered a stroke? Lynne pushed the...
    • Jerry’s Story: Spinal Tumor

      Jerry's Story: Spinal Tumor On an ordinary day in February 2009, John M. Tew, MD, got one of the true surprises of his career. He was seeing patients in his Mayfield Clinic office on the University of Cincinnati medical campus when an unexpected guest...
    • Brian’s Story: Meningioma

      Brian's Story: Meningioma “Carefree” is the word Brian uses to describe his life back then. He was 39 years old, happily married and the father of three children under the age of 5. “Life was busy, but that felt normal,” he says, reflecting. “The only...
    • Troy’s Story: Proton Therapy for Brain Cancer

      Troy's Story: Proton Therapy for Brain Cancer Troy Witt, 65, a London, Kentucky resident and a self-proclaimed "country boy,” says he loves his family, fishing, woodworking and riding on his tractor. But all of these activities have been put on hold since spring 2016 when Witt’s...
    • Troy’s Testimonial: ‘Out of 5 Stars, They Get 6’

      Troy’s Testimonial: ‘Out of 5 Stars, They Get 6’ Troy Sheldon has something to say, and he’d like...